Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic

Article Clinical Neurology

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Maria Pia Sormani et al.

Summary: This study compares the outcomes of COVID-19 in patients with multiple sclerosis (MS) in Italy with the expected outcomes in the general population. The risk of severe events, including hospitalization, ICU admission, and death, was found to be twice as high in the MS cohort compared to the age- and sex-matched Italian population. The increased risk was primarily associated with disease severity and comorbidities, but there was also a higher risk of hospitalization in patients on anti-CD20 therapies and a lower risk in patients on interferon.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19

Bertram Pitt et al.

Summary: COVID-19 is characterized by dysregulation of the immune system and thrombosis. Traditional anticoagulation strategies may increase bleeding risk, so finding new strategies that can regulate the immune system and solve thrombosis issues would be beneficial. This commentary discusses the unique properties of low dose naltrexone (LDN) and suggests it could be a novel therapeutic strategy for COVID-19.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Clinical Neurology

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Anthony T. Reder et al.

Summary: The study revealed that comorbidities, obesity, and Black/African ancestry were major risk factors for SARS-CoV-2 infection in patients with multiple sclerosis (PwMS). It also found that interferons and glatiramer acetate were associated with reduced COVID-19 risk, while anti-CD20 therapies were linked to increased risk within the treated MS cohort.

CNS DRUGS (2021)

Add to Collection

Article Clinical Neurology

β-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis

Chirag Patel et al.

Summary: The study found that serum levels of OGF were significantly elevated in MS patients on different medications, while only patients treated with glatiramer acetate had significant elevations in serum ?-endorphin levels. Serum ?-endorphin levels were directly correlated with physical health composite score. Serum vitamin D levels had an indirect relationship with 25-foot walk test times.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology